Real-World Data Analysis of Second-Line Antiangiogenic Targeted Treatments Following Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies and First-Line FOLFOX for Patients with Metastatic Colorectal Cancer

INTRODUCTION: Evidence is lacking on second-line and later treatments for patients with RAS wild-type colorectal cancer (CRC) who receive first-line anti-epidermal growth factor receptor (EGFR) antibody therapy. In this study, we explored the real-world treatment sequences, treatment duration, and f...

Descripción completa

Detalles Bibliográficos
Autores principales: Satake, Hironaga, Kagawa, Yoshinori, Shinozaki, Eiji, Tanizawa, Yoshinori, Jin, Long, Cai, Zhihong, Makiyama, Akitaka
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122877/
https://www.ncbi.nlm.nih.gov/pubmed/35384550
http://dx.doi.org/10.1007/s12325-022-02122-4

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9122877/
https://www.ncbi.nlm.nih.gov/pubmed/35384550
http://dx.doi.org/10.1007/s12325-022-02122-4

Ejemplares similares